A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia-Reference-Cited by-同舟云学术

A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia

Published:1997-11-14 Issue:5341 Volume:278 Page:1309-1312
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Lacronique Virginie¹²³,Boureux Anthony¹²³,Della Valle Véronique¹²³,Poirel Hélène¹²³,Quang Christine Tran¹²³,Mauchauffé Martine¹²³,Berthou Christian¹²³,Lessard Michel¹²³,Berger Roland¹²³,Ghysdael Jacques¹²³,Bernard Olivier A.¹²³

Affiliation:

1. V. Lacronique, V. Della Valle, H. Poirel, M. Mauchauffé, R. Berger, O. A. Bernard, U 301 de l'Institut National de la Santé et de la Recherche Médicale and SD 401 No. 301 CNRS, Institut de Génétique Moléculaire, 27 rue Juliette Dodu, 75010 Paris, France.

2. A. Boureux, C. Tran Quang, J. Ghysdael, CNRS Unité Mixte de Recherche 146, Institut Curie–Section de Recherche, Centre Universitaire, 91405 Orsay Cedex, France.

3. C. Berthou and M. Lessard, Unité d'Hématologie, Laboratoire de Cytogénétique, Hôpital Morvan, Centre Hospitalier Régional de Brest, 29609 Brest Cedex, France.

Abstract

The Janus family of tyrosine kinases (JAK) plays an essential role in development and in coupling cytokine receptors to downstream intracellular signaling events. A t(9;12)(p24;p13) chromosomal translocation in a T cell childhood acute lymphoblastic leukemia patient was characterized and shown to fuse the 3′ portion of JAK2 to the 5′ region of TEL , a gene encoding a member of the ETS transcription factor family. The TEL-JAK2 fusion protein includes the catalytic domain of JAK2 and the TEL-specific oligomerization domain. TEL-induced oligomerization of TEL-JAK2 resulted in the constitutive activation of its tyrosine kinase activity and conferred cytokine-independent proliferation to the interleukin-3–dependent Ba/F3 hematopoietic cell line.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference30 articles.

1. Rabbitts T. H., Nature 371, 143 (1994).

2. Bernard O. A., Romana S. P., Poirel H., Berger R., Leuk. Lymphoma 23, 459 (1996).

3. Golub T., et al., Biochim. Biophys. Acta 1288, 7 (1996).

4. Golub T. R., Barker G. F., Lovett M., Gilliland D. G., Cell 77, 307 (1994).

5. Romana S. P., et al., Blood 85, 3662 (1995).

Cited by 696 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TLE3 Is a Novel Fusion Partner of JAK2 in Myeloid/Lymphoid Neoplasm With Eosinophilia Responding to JAK2 Inhibition;Genes, Chromosomes and Cancer;2024-08

2. Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms;Frontiers in Oncology;2024-07-18

3. Relationship between amide ratio assessed by Fourier‐transform infrared spectroscopy: A biomarker candidate for polycythemia vera disease;Journal of Biophotonics;2024-07-08

4. ISG15 promotes tumor progression via IL6/JAK2/STAT3 signaling pathway in ccRCC;Clinical and Experimental Medicine;2024-06-29

5. Acute lymphoblastic leukaemia;Nature Reviews Disease Primers;2024-06-13